Regentis Biomaterials Ltd.

RGNT

AMEXHealthcareMedical - Instruments & Supplies

GoAI で開く

前日終値

$2.10

+$0.04 · +1.94%

8月21日 16:00 ET

市場前

$2.1789

+$0.0789 · +3.76%

8月24日 6:41 ET

過去の価格は調整または遅延している場合があります。

企業プロフィール

会社ウェブサイト

Regentis Biomaterials Ltd. is a regenerative medicine firm dedicated to crafting innovative solutions for tissue repair, ultimately aiming to enhance patients' health and overall quality of life. The company's primary product in development is GelrinC, a novel, cell-free, ready-to-use hydrogel designed to be solidified into an implant within the knee. This implant serves to address painful knee injuries and mend articular cartilage damage. Regentis Biomaterials leverages its proprietary Gelrin platform, which employs biodegradable hydrogel implants, to develop orthopedic therapies that facilitate the regeneration of compromised or diseased tissues. The company was established in 2004 and operates from its headquarters in Herzliya, Israel.

業界: Medical - Instruments & Supplies
セクター: Healthcare
本社: IL
最高経営責任者（CEO）: Ehud Geller
上場以来: 2025年12月4日
従業員: 10

市場での位置

日中レンジ

現在 $2.10

$2.05$2.17

52週レンジ

現在 $2.10

$1.232$15.50

始値: $2.05
前日終値: $2.06
出来高: 3.71万; 0.01× 平均
平均出来高: 540.1万; 1日平均出来高
時価総額: 1475.02万 USD
ベータ: -0.69; 市場参照 1
50日平均: $2.8998; 平均以下（-27.58%）
200日平均: $3.8404; 平均以下（-45.32%）

RGNT ニュース

accessnewswire.com2026年7月20日

Regentis Receives Japanese Patent allowance, Strengthening its Global GelrinC Intellectual Property Portfolio with New Proprietary Manufacturing Technology

Patent expands intellectual property protection in one of the world's largest cartilage repair markets GelrinC is a cell-free hydrogel delivered in a single ~10-minute procedure eliminating the need for cell harvesting,…

ソースを読む

accessnewswire.com2026年7月15日

Regentis Receives European Regulatory Approval for New GelrinC Manufacturing Process, Increasing Production Yield by 400% Ahead of European Commercial Launch

European Notified Body approves next-generation manufacturing process that increases production 5-fold, lowers manufacturing costs, improves safety and enables scalable commercial production GelrinC®, which is approved…

ソースを読む

accessnewswire.com2026年6月17日

Regentis Biomaterials Announces Pricing of a $6.5 Million Private Placement

HERZLIYA, IL / ACCESS Newswire / June 17, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today…

ソースを読む

accessnewswire.com2026年6月8日

Regentis to Commence European Surgeon Training for GelrinC in Knee Cartilage Repair as Commercial Launch Preparations Accelerate

GelrinC®, positioned as the first off-the-shelf cell-free hydrogel implant for knee cartilage repair, is approved for sale in the European Union Regentis is growing its network of European Centers of Excellence designed…

ソースを読む